11:06:10 EST Thu 21 Nov 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Stagezero partner signs ColonSentry distribution deal

2019-10-21 11:06 ET - News Release

Mr. James Howard-Tripp reports

STAGEZERO LIFE SCIENCES ENTERS EUROPEAN MARKET WITH ONCORE PHARMA AND BODYCHECK NL: UPDATE TO CLARIFY DETAILS WITHIN THE AGREEMENT

Stagezero Life Sciences Ltd.'s licensing partner, Oncore Pharma, has signed a multiyear agreement with BodyCheck NL for the distribution and sale of ColonSentry throughout the Netherlands, Belgium and Luxembourg (Benelux).

The multiyear agreement has a term of six years, with a lead-in phase of six months, which will be used to implement and launch a sales and marketing campaign in Belgium, the Netherlands and Luxembourg. BodyCheck NL has committed to a range of testing, with 275,000 ColonSentry diagnostic tests for the early detection of colorectal cancer anticipated to be analyzed and reported out by Stagezero Life Sciences' state-of-the-art facility in Richmond, Va., United States, over the duration of the agreement. The multiyear agreement has a value to Stagezero of $40-million (U.S.) based on the committed 275,000 tests. Both the anticipated test volume and the resulting revenue are commitments, not guarantees.

ColonSentry is Stagezero's proprietary liquid biopsy that uses advanced gene expression (mRNA) technology for the early identification of colorectal cancer (CRC).

"Oncore Pharma, moving quickly to use its established relationships in Europe to introduce ColonSentry into markets other than the U.S., is opening up additional opportunities for us," said James Howard-Tripp, chairman and chief executive officer of Stagezero Life Sciences. "With this as our initial entry point in the European market, we look forward to gaining experience and enlarging our footprint outside of the U.S. even further in 2020."

About Stagezero Life Sciences Ltd.

Stagezero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle, the company's next-generation test, is a panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on the company's proven and proprietary sentinel principle technology platform, which has been validated in 10,000 patients and used to develop the first liquid biopsy for colorectal cancer, with further validation currently under way.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.